Tests pantoprazole to see if it protects kidneys during cisplatin treatment
Tests pantoprazole to limit kidney harm from cisplatin in head and neck cancer.
Plain-language title generated from the registry record
Registry title: Pantoprazole in Cisplatin Nephrotoxicity
Key facts
- Where
- Tanta, EgyptSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with head and neck cancer who will get cisplatin. It tests whether pantoprazole protects the kidneys.
- Sex
- All sexes can join.
- Disease stage
- Head and neck cancer.
Main reasons for not taking part
- GFR less than 59
- DM
- Liver enzymes more than 3 fold raised
Read by machine on 9 November 2026.
Where in Egypt
- Sherief Abd-ElsalamTanta, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sherief Abd-Elsalam
- Trial code
- NCT04217512
- Record updated
- 3 January 2020
- Original description
Pantoprazole in Cisplatin NephrotoxicityRead full original descriptionShow less
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
Pantoprazole in Cisplatin Nephrotoxicity
Inclusion: Patients with head and neck cancer.
Exclusion: GFR less than 59; DM; Elevated liver enzymes more than 3 fold.